Synairgen Presents SNG001 Data at ESWI

Press Release

Synairgen plc 

('Synairgen' or the 'Company') 

Synairgen to Present Clinical and in vitro Data on the Antiviral Activity of SNG001 at the 8th ESWI Influenza Conference

Southampton, UK - 6 December 2021: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections, announced today an oral presentation and a poster presentation at the 8th European Scientific Working Group in Influenza (ESWI) Influenza Conference, which is taking place virtually from 4-7 December 2021.

The oral presentation will highlight clinical data demonstrating the antiviral activity of SNG001 in the lungs of patients with asthma and those with chronic obstructive pulmonary disease (COPD).

The poster presentation will highlight in vitro data showing the antiviral activity of SNG001 against Alpha, Beta and Gamma SARS-CoV-2 variants.

Details of the presentations are as follows:

Oral Presentation:

Title: Local delivery of interferon beta (SNG001) by inhalation upregulates lung antiviral biomarkers

Presenter: Phillip D Monk, Ph.D., Chief Scientific Officer, Synairgen

Abstract: 270

Date/Time: 6 December 2021; 17:00-18:45 GMT

Track: Scientific Programme

Poster Presentation:

Title: Interferon beta has potent antiviral activity against SARS-CoV-2 including variants of concern

Abstract: 269

Date/Time: On-demand

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 ('MAR').

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

[email protected]  Tel: + 44 (0) 23 8051 2800

Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

[email protected]

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations) 

Mary Conway

[email protected]

Tel: +1 516-606-6545

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). Synairgen's Phase 3 clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of recovery to 'no limitation of activities' versus placebo.1

Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com.

1https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext